KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Precigen (PGEN) Research & Development (2016 - 2025)

Precigen (PGEN) has disclosed Research & Development for 14 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 40.55% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.3 million through Dec 2025, down 22.12% year-over-year, with the annual reading at $41.3 million for FY2025, 22.12% down from the prior year.
  • Research & Development for Q4 2025 was $7.0 million at Precigen, down from $12.4 million in the prior quarter.
  • The five-year high for Research & Development was $15.7 million in Q2 2024, with the low at $7.0 million in Q4 2025.
  • Average Research & Development over 5 years is $11.9 million, with a median of $11.9 million recorded in 2022.
  • The sharpest move saw Research & Development surged 44.03% in 2021, then plummeted 40.55% in 2025.
  • Over 5 years, Research & Development stood at $12.2 million in 2021, then decreased by 11.37% to $10.8 million in 2022, then increased by 20.39% to $13.0 million in 2023, then decreased by 9.51% to $11.8 million in 2024, then tumbled by 40.55% to $7.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $7.0 million, $12.4 million, and $11.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.